Versant Ventures related stories
All articles and analysis
Dermatology and aesthetics company Sebacia takes in $20 mln Series DDuluth, Georgia-based Sebacia Inc, a dermatology and aesthetics company, has closed $20 million in Series D financing. Versant Ventures, Domain Associates, Accuitive Medical Ventures and Partners Healthcare Innovation Fund led the round with participation from other investors that included Salem Partners. Also, Sebacia secured a $16 million debt facility from Hercules Capital.
- Canadian VC sustains robust pace as top Q2 deals raise $518 mln
Canada’s top 10 venture-capital financings in the second quarter drew $518 million from investors, up 8 percent from the $480 million that went into the top 10 deals a year earlier. The number is based on PE Hub Canada’s list of the largest deals announced from April through June, supplemented by preliminary data from Thomson Reuters. It suggests Canadian VC investment activity this year is so far keeping pace with the robust trend lines of 2016. At the end of June, VC funds invested $1.75 billion in Canada, preliminary data show, not far behind the $1.78 billion invested in the first half of last year.
Fonds de solidarité FTQ invests $11.6 mln in Repare’s Series AThe Fonds de solidarité FTQ disclosed an investment of about $11.6 million (US$8.75 million) in Repare Therapeutics Inc, a Montréal developer of precision oncology drugs that target specific vulnerabilities of tumour cells. The investment formed part of Repare's $90 million (US$68 million) Series A financing /canada/2017/6/biotech-boom-continues-with-repares-90-mln-series-a-zymeworks-ipo/ co-led by Versant Ventures and MPM Capital. The Fonds said the deal is part of its life sciences strategy. The strategy combines commitments to funds like Versant Venture Capital VI, which raised US$400 million /canada/2017/1/3428644/ earlier this year, and direct investments.
- Repare Therapeutics scores $68 mln Series A
Montreal and Boston-based Repare Therapeutics, a developer of drugs that treat cancer, has raised $68 million in Series A financing. Versant Ventures and MPM Capital led the round with participation from other investors that included Fonds de solidarité FTQ, Celgene Switzerland and BDC Capital.
Biotech boom continues with Repare’s $90 mln Series A, Zymeworks IPOCanada’s life sciences sector is on a roll. Current levels of venture capital investment are unprecedented. This week another major deal was announced, with Repare Therapeutics, a Montréal developer of precision oncology drugs, securing about $90 million in a Series A financing. One of the sector’s other big stories is the IPO of biotherapeutics provider Zymeworks. The company, which last month raised about $86 million on the Toronto and New York exchanges, is now being talked about as Canada’s next biotech anchor company.
- Monteris Medical nabs $26.6 mln Series C
Plymouth, Minneapolis-based Monteris Medical, a provider of minimally invasive robotic laser thermotherapy, has closed $26.6 million in Series C financing. Versant Ventures and SightLine Partners led the round with participation from existing backers Birchview Capital and BDC Capital.
Monteris raises $26.6 mln in Versant, SightLine-led Series CMonteris Medical Inc has secured US$26.6 million in a Series C financing. The round was led by new investors Versant Ventures and SightLine Partners, with participation from current investors Birchview Capital and BDC Capital’s Healthcare Venture Fund. Based in Plymouth, Minnesota and Winnipeg, Manitoba, Monteris is a provider of minimally invasive laser ablation systems for treating brain lesions. It said it will use the funds raised to invest in further innovation, clinical research and commercial expansion. Founded in 1999, Monteris' technology was developed from research begun at Winnipeg's St. Boniface General Hospital.
- VC-backed Cerêve appoints Spence as president and CEO
Oakmont, Pennsylvania-based Cerêve Inc, a maker of insomnia therapy, has named Donald J. Spence as president and CEO. Previously, Spence was group president of sleep and home respiratory and then later CEO of Philips Home Healthcare for Philips Respironics. Cerêve is backed by KKR, Arboretum Ventures, Versant Ventures and Partner Ventures.